Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.

Blight AR, Hsieh J, Curt A, Fawcett JW, Guest JD, Kleitman N, Kurpad SN, Kwon BK, Lammertse DP, Weidner N, Steeves JD.

Spinal Cord. 2019 May;57(5):348-359. doi: 10.1038/s41393-019-0276-2. Epub 2019 Apr 8. Review.

PMID:
30962518
2.

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J; ENHANCE study investigators.

CNS Drugs. 2019 Jan;33(1):61-79. doi: 10.1007/s40263-018-0586-5.

3.

Lower extremity outcome measures: considerations for clinical trials in spinal cord injury.

Bolliger M, Blight AR, Field-Fote EC, Musselman K, Rossignol S, Barthélemy D, Bouyer L, Popovic MR, Schwab JM, Boninger ML, Tansey KE, Scivoletto G, Kleitman N, Jones LAT, Gagnon DH, Nadeau S, Haupt D, Awai L, Easthope CS, Zörner B, Rupp R, Lammertse D, Curt A, Steeves J.

Spinal Cord. 2018 Jul;56(7):628-642. doi: 10.1038/s41393-018-0097-8. Epub 2018 Apr 27. Review.

4.

Targeting Translational Successes through CANSORT-SCI: Using Pet Dogs To Identify Effective Treatments for Spinal Cord Injury.

Moore SA, Granger N, Olby NJ, Spitzbarth I, Jeffery ND, Tipold A, Nout-Lomas YS, da Costa RC, Stein VM, Noble-Haeusslein LJ, Blight AR, Grossman RG, Basso DM, Levine JM.

J Neurotrauma. 2017 Jun 15;34(12):2007-2018. doi: 10.1089/neu.2016.4745. Epub 2017 Mar 22. Review.

5.

Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study.

Bethoux F, Fatemi A, Fowler E, Marciniak C, Mayadev A, Waksman J, Zackowski K, Suarez G, Blight AR, Rabinowicz AL, Carrazana E.

Clin Ther. 2017 Feb;39(2):337-346. doi: 10.1016/j.clinthera.2016.12.015. Epub 2017 Jan 25.

6.

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.

Clin Ther. 2015 Dec 1;37(12):2780-7. doi: 10.1016/j.clinthera.2015.10.014. Epub 2015 Nov 10.

7.

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR 3rd, Blight AR, Carrazana EJ.

Int J MS Care. 2015 May-Jun;17(3):138-45. doi: 10.7224/1537-2073.2014-040.

8.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR; MS-F203, MS-F204, and Extension Study Investigators.

Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591. Epub 2015 Jan 12.

9.

Challenges for defining minimal clinically important difference (MCID) after spinal cord injury.

Wu X, Liu J, Tanadini LG, Lammertse DP, Blight AR, Kramer JL, Scivoletto G, Jones L, Kirshblum S, Abel R, Fawcett J, Field-Fote E, Guest J, Levinson B, Maier D, Tansey K, Weidner N, Tetzlaff WG, Hothorn T, Curt A, Steeves JD.

Spinal Cord. 2015 Feb;53(2):84-91. doi: 10.1038/sc.2014.232. Epub 2014 Dec 16. Review.

PMID:
25510192
10.

A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.

Goodman AD, Brown TR, Schapiro RT, Klingler M, Cohen R, Blight AR.

Int J MS Care. 2014 Fall;16(3):153-60. doi: 10.7224/1537-2073.2013-023.

11.

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.

Blight AR, Henney HR 3rd, Cohen R.

Ann N Y Acad Sci. 2014 Nov;1329:33-44. doi: 10.1111/nyas.12512. Epub 2014 Aug 25. Review.

12.
13.

Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.

Cardenas DD, Ditunno JF, Graziani V, McLain AB, Lammertse DP, Potter PJ, Alexander MS, Cohen R, Blight AR.

Spinal Cord. 2014 Jan;52(1):70-6. doi: 10.1038/sc.2013.137. Epub 2013 Nov 12.

PMID:
24216616
14.

Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.

Samara E, Winkle P, Pardo P, Henney HR 3rd, Way SL, Brown E, Lee A, Blight AR.

J Clin Pharmacol. 2014 Jan;54(1):53-60. doi: 10.1002/jcph.189. Epub 2013 Oct 22.

15.

Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.

Iaci JF, Parry TJ, Huang Z, Finklestein SP, Ren J, Barrile DK, Davenport MD, Wu R, Blight AR, Caggiano AO.

Stroke. 2013 Jul;44(7):1942-50. doi: 10.1161/STROKEAHA.111.000147. Epub 2013 May 7.

PMID:
23652269
16.

Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.

Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.

Neurology. 2013 Apr 16;80(16):1509-17. doi: 10.1212/WNL.0b013e31828cf7f3. Epub 2013 Mar 27. Review.

PMID:
23535489
17.

Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical Trial.

Steeves JD, Lammertse DP, Kramer JL, Kleitman N, Kalsi-Ryan S, Jones L, Curt A, Blight AR, Anderson KD.

Top Spinal Cord Inj Rehabil. 2012 Winter;18(1):1-14. Epub 2012 Jan 31.

18.

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets.

Henney HR 3rd, Blight AR.

Degener Neurol Neuromuscul Dis. 2012 Jun 22;2:53-64. doi: 10.2147/DNND.S19839. eCollection 2012. Review.

19.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693
20.

Effect of food on the single-dose pharmacokinetics and tolerability of dalfampridine extended-release tablets in healthy volunteers.

Henney HR 3rd, Faust B, Blight AR.

Am J Health Syst Pharm. 2011 Nov 15;68(22):2148-54. doi: 10.2146/ajhp110054.

PMID:
22058101
21.

Treatment of walking impairment in multiple sclerosis with dalfampridine.

Blight AR.

Ther Adv Neurol Disord. 2011 Mar;4(2):99-109. doi: 10.1177/1756285611403960.

22.

4-Aminopyridine: new life for an old drug. Reply.

Cohen R, Blight AR.

Ann Neurol. 2011 Jan;69(1):218-20. doi: 10.1002/ana.22322. No abstract available.

PMID:
21280101
23.

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators.

Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.

PMID:
20976768
24.

Characterization of neurological recovery following traumatic sensorimotor complete thoracic spinal cord injury.

Zariffa J, Kramer JL, Fawcett JW, Lammertse DP, Blight AR, Guest J, Jones L, Burns S, Schubert M, Bolliger M, Curt A, Steeves JD.

Spinal Cord. 2011 Mar;49(3):463-71. doi: 10.1038/sc.2010.140. Epub 2010 Oct 12.

PMID:
20938451
25.

Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury.

Steeves JD, Kramer JK, Fawcett JW, Cragg J, Lammertse DP, Blight AR, Marino RJ, Ditunno JF Jr, Coleman WP, Geisler FH, Guest J, Jones L, Burns S, Schubert M, van Hedel HJ, Curt A; EMSCI Study Group.

Spinal Cord. 2011 Feb;49(2):257-65. doi: 10.1038/sc.2010.99. Epub 2010 Aug 17.

PMID:
20714334
26.

A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury.

Kwon BK, Okon EB, Tsai E, Beattie MS, Bresnahan JC, Magnuson DK, Reier PJ, McTigue DM, Popovich PG, Blight AR, Oudega M, Guest JD, Weaver LC, Fehlings MG, Tetzlaff W.

J Neurotrauma. 2011 Aug;28(8):1525-43. doi: 10.1089/neu.2010.1296. Epub 2010 Oct 18. Review.

27.
28.

Effects of 4-Aminopyridine on Cloned hERG Channels Expressed in Mammalian Cells.

Renganathan M, Sidach S, Blight AR.

Arch Drug Inf. 2009 Sep;2(3):51-57.

29.

Outcome measures in spinal cord injury: recent assessments and recommendations for future directions.

Alexander MS, Anderson KD, Biering-Sorensen F, Blight AR, Brannon R, Bryce TN, Creasey G, Catz A, Curt A, Donovan W, Ditunno J, Ellaway P, Finnerup NB, Graves DE, Haynes BA, Heinemann AW, Jackson AB, Johnston MV, Kalpakjian CZ, Kleitman N, Krassioukov A, Krogh K, Lammertse D, Magasi S, Mulcahey MJ, Schurch B, Sherwood A, Steeves JD, Stiens S, Tulsky DS, van Hedel HJ, Whiteneck G.

Spinal Cord. 2009 Aug;47(8):582-91. doi: 10.1038/sc.2009.18. Epub 2009 Apr 21. Review.

30.

Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.

Blight AR, Henney HR 3rd.

Clin Ther. 2009 Feb;31(2):328-35. doi: 10.1016/j.clinthera.2009.02.004.

PMID:
19302905
31.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634
32.

Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group.

Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.

PMID:
18672472
33.

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR.

Mult Scler. 2007 Apr;13(3):357-68. Epub 2007 Jan 29.

PMID:
17439905
34.

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials.

Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, Bartlett PF, Blight AR, Dietz V, Ditunno J, Dobkin BH, Havton LA, Ellaway PH, Fehlings MG, Privat A, Grossman R, Guest JD, Kleitman N, Nakamura M, Gaviria M, Short D.

Spinal Cord. 2007 Mar;45(3):190-205. Epub 2006 Dec 19. Review.

PMID:
17179973
35.

Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures.

Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, Ellaway PH, Fehlings MG, Guest JD, Kleitman N, Bartlett PF, Blight AR, Dietz V, Dobkin BH, Grossman R, Short D, Nakamura M, Coleman WP, Gaviria M, Privat A; International Campaign for Cures of Spinal Cord Injury Paralysis.

Spinal Cord. 2007 Mar;45(3):206-21. Epub 2006 Dec 19. Review.

PMID:
17179972
36.

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics.

Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, Kalichman M, Rask C, Curt A, Ditunno JF, Fehlings MG, Guest JD, Ellaway PH, Kleitman N, Bartlett PF, Blight AR, Dietz V, Dobkin BH, Grossman R, Privat A; International Campaign for Cures of Spinal Cord Injury Paralysis.

Spinal Cord. 2007 Mar;45(3):222-31. Epub 2006 Dec 19. Review.

PMID:
17179971
37.

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design.

Lammertse D, Tuszynski MH, Steeves JD, Curt A, Fawcett JW, Rask C, Ditunno JF, Fehlings MG, Guest JD, Ellaway PH, Kleitman N, Blight AR, Dobkin BH, Grossman R, Katoh H, Privat A, Kalichman M; International Campaign for Cures of Spinal Cord Injury Paralysis.

Spinal Cord. 2007 Mar;45(3):232-42. Epub 2006 Dec 19. Review.

39.

Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.

Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P, Sipski M, Cohen R, Blight AR.

Spinal Cord. 2007 Feb;45(2):158-68. Epub 2006 Jun 13.

PMID:
16773037
40.

Clinical trials in spinal cord injury.

Blight AR, Tuszynski MH.

J Neurotrauma. 2006 Mar-Apr;23(3-4):586-93. Review.

PMID:
16629639
41.

Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord.

Caggiano AO, Zimber MP, Ganguly A, Blight AR, Gruskin EA.

J Neurotrauma. 2005 Feb;22(2):226-39.

PMID:
15716629
42.

Just one word: plasticity.

Blight AR.

Nat Neurosci. 2004 Mar;7(3):206-8. No abstract available.

PMID:
14983180
43.

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.

Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R.

Arch Phys Med Rehabil. 2004 Jan;85(1):29-34.

PMID:
14970964
44.

Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.

Hayes KC, Potter PJ, Hansebout RR, Bugaresti JM, Hsieh JT, Nicosia S, Katz MA, Blight AR, Cohen R.

Clin Neuropharmacol. 2003 Jul-Aug;26(4):185-92.

PMID:
12897638
45.

Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.

Hayes KC, Katz MA, Devane JG, Hsieh JT, Wolfe DL, Potter PJ, Blight AR.

J Clin Pharmacol. 2003 Apr;43(4):379-85.

PMID:
12723458
46.

Miracles and molecules--progress in spinal cord repair.

Blight AR.

Nat Neurosci. 2002 Nov;5 Suppl:1051-4. Review.

PMID:
12403984
47.

Acute spinal cord injury: pharmacotherapy and drug development perspectives.

Blight AR, Zimber MP.

Curr Opin Investig Drugs. 2001 Jun;2(6):801-8. Review.

PMID:
11572660
48.

Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.

Halter JA, Blight AR, Donovan WH, Calvillo O.

Spinal Cord. 2000 Dec;38(12):728-32.

PMID:
11175372
49.

Control of membrane sealing in injured mammalian spinal cord axons.

Shi R, Asano T, Vining NC, Blight AR.

J Neurophysiol. 2000 Oct;84(4):1763-9.

50.

Intravenous infusion of 4-AP in chronic spinal cord injured subjects.

Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo O, McCann MT, Sherwood AM, Castillo T, Parsons KC, Strayer JR.

Spinal Cord. 2000 Jan;38(1):7-15.

PMID:
10762192

Supplemental Content

Loading ...
Support Center